|
Dr. Mark Blumenkranz is a member of the Board of Directors of the OptiMedica Corporation. Recognized as a leading authority in ophthalmology, he is currently Professor and Chairman of the Department of Ophthalmology at Stanford University. He also is an associate examiner for the American Board of Ophthalmology and a member of the Retina, Vitreous, Macula, and Gonin Societies.
Dr. Blumenkranz has served on the Editorial Boards of a number of key industry journals, including: Retina, Graefe's Archives for Ophthalmology, and Ophthalmology. He has received numerous awards, among them the Research to Prevent Blindness Special Manpower Award, the Heed Award, the Rosenthal Award in Visual Sciences, and the American Academy of Ophthalmology Senior Honor Award. Dr. Blumenkranz has served as a Principal Investigator on a number of clinical research trials at Stanford evaluating the effects of laser and pharmacological agents on eye disease. He also has authored more than 100 peer-reviewed publications and book chapters in the area of vitreoretinal surgery, with special interests in surgical adjuvant pharmacology and new microsurgical and laser techniques, and is an inventor on 13 patents.
Dr. Blumenkranz has a longstanding interest in technology transfer and has, over the past 10 years, served on the board of directors and scientific advisory boards of a number of private and publicly-held ophthalmic device and drug companies including OIS, MidLabs and most recently Oculex where he served as Chairman of the SAB and principal trial designer for the Posurdex Study. He was a founding member of the SAB of Eyetech Pharmaceuticals. Dr. Blumenkranz received his B.A, M.S., and M.D. degrees from Brown University. | 